昂利康：左氧氟沙星片获药品注册证书 视同通过一致性评价

Core Viewpoint - The company Anglikang (002940) has received the drug registration certificate for Levofloxacin Tablets from the National Medical Products Administration, which is expected to enhance its product pipeline and align with national policies [2][3]. Group 1: Product Development - Levofloxacin Tablets are a third-generation fluoroquinolone antibiotic with a broad antibacterial spectrum and strong antibacterial action, used for treating various infections in adults [2]. - The approval of Levofloxacin Tablets is seen as a significant milestone, as it is considered equivalent to passing the consistency evaluation [2]. Group 2: Business Overview - Anglikang primarily engages in the production and manufacturing of pharmaceuticals, including chemical raw materials, chemical preparations, pharmaceutical excipients, and specialty intermediates [3]. - In the first half of 2025, the company achieved a total operating revenue of 724 million yuan [3].